The IMID Forum

Join Professor Iain McInnes for the first episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that aimed to advise on treatment of rheumatic diseases in a real-world setting. In our first paper, Emma Dures and her colleagues compiled the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. Our second paper is from Kehinde Sunmboye and his colleagues, where they investigated the incidence of MACE in a multi-ethnic population that were treated with JAK inhibitors. To access detailed summary slides for the papers discussed today, visit imidforum.com.

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered the post hoc analysis of PsA patients receiving guselkumab, focusing on disease control across domains and patient characteristics, and a systematic review and meta-analysis on genetic markers and their response to biologics in inflammatory diseases.

Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, namely the effect of sex on the long-term persistence of targeted therapies, as well as the impact of secukinumab on synovitis and enthesitis.

Join Professors Hideto Kameda and Xenofon Baraliakos for insights on upadacitinib in nr-axSpA and certolizumab pegol treatment. Topics include results from a phase 3 trial, analysis of upadacitinib treatment, longer-term safety analysis, clinical outcomes of certolizumab pegol, and response rates based on MRI and CRP status in nr-axSpA patients.

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the long-term impact of secukinumab treatment on bone-related outcomes and BTMs in r-AxSpA patients over two years. Our faculty then move on to discuss another publication, which presents JAKi treatment recommendations for IMIDs from a two-round modified RAM study with 21 subject matter experts.

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that that add to the knowledge of common treatments relating to RA. In our first paper, Juergen Rech and colleagues present the results of the ARIAA study, which shows that abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. Our second paper is from Juergen Rech and colleagues, where they present the results of the ARIAA study which investigated whether abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. To access detailed summary slides for the papers discussed today, visit imidforum.com.

Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the long-term safety of ixekizumab as well as bimekizumab treatment in a TNFi-IR population.

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Atul Deodhar to discuss the retention rate of secukinumab over two different time periods. Our faculty then move on to discuss another publication, which compares the improvements is sacroiliac joint symptoms across patients with AS and axSpA treated with different DMARDs.

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Adam Goldman, an epidemiology researcher at The Chaim Sheba Medical Center in Tel-Hashomer, and an epidemiology researcher and lecturer at Tel-Aviv University, as they discuss his recent paper ‘Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports’, published in Seminars in Arthritis and Rheumatism on 17th May 2024.

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Daniel Blockmans, from the Department of Internal Medicine at the University Hospitals Leuven, as they discuss his recent paper ‘Efficacy and safety of upadacitinib in patients with giant cell arteritis (SELECT-GCA): A double-blind, randomized controlled Phase 3 trial’, published in Annals of the Rheumatic Diseases on June 2024.